Kura Sushi stock soars toward a record, after profit surprisingly increased and beat expectations by a wide margin
Shares of Kura Sushi USA Inc. (KRUS) shot up 17.4% toward a record high in afternoon trading Friday, after the Japanese restaurant chain reported a fiscal third-quarter profit that more than tripled and beat expectations by a wide margin. The California-based company, which went public in August 2019, reported late Thursday net income for the quarter to May 31 that rose to $1.68 million, or 16 cents a share, from $477 million, or 5 cents a share, in the year ago period. The FactSet consensus was for earnings per share to decline to 4 cents. Sales rose 29.7% to $49.2 million, just below the FactSet consensus of $49.6 million, while same-store sales growth of 10.3% beat expectations of a 7.9% rise. No less than 5 of the seven analysts surveyed by FactSet who cover Kura Sushi raised their stock price targets after the results, with the average target rising to $97.83 from $82.00 at the end of June. The stock has more than doubled year to date, up 110.0%, while the S&P 500 has advanced 15.3%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-07-23 1437ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast